The University of Missouri Research Reactor (MURR) is the latest member of Nuclear Medicine Europe, an industry association for the radiopharmaceutical and molecular imaging industry in Europe, the University of Missouri announced July 17.

The Defense Advanced Research Projects Agency (DARPA) Defense Sciences Office (DSO) wants to mimic and accelerate the natural half-life decay chain of alpha-emitting radioisotopes and plans to invite proposals for experimental or theoretical research tracks under Decay on Demand—a new DARPA disruptioneering opportunity. The solicitation was published in draft form on June 27.

The Department of Energy’s Isotope Program (DOE IP) announced last week that it would end its “active standby” capability for strontium-82 production about two decades after beginning production of the isotope for cardiac diagnostic imaging. The DOE IP is celebrating commercialization of the Sr-82 supply chain as “a success story for both industry and the DOE IP.” Now that the Sr-82 market is commercially viable, the DOE IP and its National Isotope Development Center can “reassign those dedicated radioisotope production capacities to other mission needs”—including Sr-89.

According to the Council on Radionuclides and Radiopharmaceuticals, more than 82,000 nuclear imaging procedures using nuclear medicine are performed throughout the world every day. To administer these vital medical procedures, radiopharmaceutical companies and hospitals rely on a handful of producers of medical radioisotopes.

Westinghouse and TerraPower, in conjunction with Belgium’s Pan Tera, have announced plans to produce large quantities of actinium-225, a radioisotope used for targeted alpha radiation therapy for certain types of cancer.

Serva Energy has developed a research reactor–based method of actinium-225 production, the company announced on June 22, saying it “marks the first time a commercial entity has employed a conventional nuclear reactor to produce the lifesaving isotope—allowing for dozens of existing research reactors around the world to collaborate with Serva on increasing production of Actinium-225 without huge capital investments or delays for construction.”

Accelerators and other new facilities are producing an increasing share of the radioisotopes that were once sourced solely from a handful of research reactors around the globe; demand for alpha-emitters is increasing; and the need for an ensured supply of both radioactive and stable isotopes is now heightened as many countries seek an alternative to Russian isotopes. Those are just a few of the key points that emerged from a recent webinar, “Demand and Supply of Isotopes Around the World: From Diverse Perspectives,” organized by the World Council of Isotopes, along with the Sylvia Fedoruk Canadian Centre for Nuclear Innovation and the University of Saskatchewan, the hosts of the upcoming 11th International Conference on Isotopes (11ICI).

Scientists at Lawrence Livermore National Laboratory and Pennsylvania State University have demonstrated that a natural protein found bonded to rare earth elements can be recovered and used as a tool to purify and effectively manage radioactive metals that show promise for cancer therapy and the detection of illicit nuclear activities.

SHINE Medical Technologies plans to locate its European medical isotope production facility in the Netherlands after a yearlong search and a review of more than 50 proposals from sites across Europe. The company announced on May 20 that construction at the site should begin in 2023 with commercial production starting in late 2025.